VK2735
Peptide Target: GLP-1 receptor, GIP receptor, GLP-1R, GIPR
Viking Therapeutics
Most recent annual filing: 2026-02-11
- Oral VK2735 corporate update4Q 2026Oral VK2735 corporate update, 4Q 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
VK2809
VK0214
VK5211
Small Molecule Target: androgen receptor
- Hip Fracture
VK0612
- Undisclosed indication
VK3019
Biotech Distilled coverage (6)
- 2026-07-30 UPDATE: Viking Therapeutics (VKTX) - A $500M Buyback and a New ATM in the Same Filing 🔒 Paid
- 2026-05-01 UPDATE: Viking Therapeutics (VKTX) - Ligand Pulls the Pin on VK2809 🔒 Paid
- 2026-04-30 UPDATE: Viking Therapeutics (VKTX) - The Burn Rate Catches Up 🔒 Paid
- 2026-02-11 Update: Viking Therapeutics (VKTX) – The "Wait and Bleed" Quarter 🔒 Paid
- 2026-01-10 Update: Viking Therapeutics (VKTX) – Commercial Bluff or Go It Alone Suicide Pact? 🔒 Paid
- 2025-12-23 Viking Therapeutics (VKTX): Scientific Due Diligence for Lead and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.